|
ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Clinical research trials and ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck. ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck clinical trial. Test subjects typically receive the most effective healthcare possible for their ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "Z" Clinical Trials Conditions > ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck  ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
For Condition: Throat Cancer,Nose Cancer,Oral Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , University of Chicago Cancer Research Center
Synopsis: RATIONALE: Biological therapies such as ZD1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.
Details: OBJECTIVES: I. Determine the activity of ZD 1839 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. II. Determine the effectiveness of this regimen in these patients. III. Determine the toxicity of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive oral ZD 1839 once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 22-46 patients will be accrued for this study within 1-2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck that is incurable by surgery or radiotherapy - At least 1 lesion measurable in at least 1 dimension At least 20 mm by conventional techniques OR At least 10 mm by CT scan - No known brain metastases --Prior/Concurrent Therapy-- - Biologic therapy: No prior epidermal growth factor receptor-based therapy for recurrent disease - Chemotherapy: No more than 1 prior adjuvant or neoadjuvant chemotherapy and/or chemoradiotherapy regimen; At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics; See Chemotherapy; At least 4 weeks since prior radiotherapy and recovered - Surgery: See Disease Characteristics - Other: No more than 1 prior regimen for recurrent disease; No other concurrent investigational agents; No concurrent combination antiretroviral therapy for HIV --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2; Karnofsky 60-100% - Life expectancy: More than 3 months - Hematopoietic: WBC at least 3,000/mm3; Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin normal; AST/ALT no greater than 2.5 times upper limit of normal - Renal: Creatinine no greater than 1.5 mg/dL - Cardiovascular: No symptomatic congestive heart failure; No unstable angina pectoris; No cardiac arrhythmia - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No history of allergic reactions to compounds of similar chemical or biological composition to ZD 1839; No active infection; No other uncontrolled illness; No psychiatric illness or social situation that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
FredRosen, Study Chair, University of Chicago Cancer Research Center
Ingalls Memorial Hospital
Harvey, Illinois, 60426
United States
Michiana Hematology/Oncology P.C.
South Bend, Indiana, 46617
United States
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602
United States
Evanston Northwestern Health Care
Evanston, Illinois, 60201
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
Oncology Care Associates, P.L.L.C.
Saint Joseph, Michigan, 49085
United States
Cancer Care Specialists of Central Illinois, S.C.
Decatur, Illinois, 62526
United States
Columbia LaGrange Memorial Hospital
LaGrange, Illinois, 60525
United States
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
Fort Wayne Medical Oncology and Hematology, Inc.
Ft. Wayne, Indiana, 46885-5099
United States
Additional Information:
Study ID Numbers: CDR0000068577; NCI-1721,UCCRC-NCI-1721,UCCRC-10869
Study Start Date: March 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00015964
Other Oral Cancer Studies:
1. Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
2. Combination Chemotherapy Plus Radiation Therapy in Treating Patients with Head and Neck Cancer
3. Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
4. Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
5. Chemotherapy in Treating Patients With Solid Tumors
Related Studies:
Other Oral Cancer Clinical Trials
Other Illinois Clinical Trials
Other Peoria Clinical Trials
ZD1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
|
|
|
|
|
|
|
|
